Share Twitter LinkedIn Facebook Email Katherine Clifton, MD @katherineclift4 of @WUSTL discusses actionable fusions as an anti-EGFR resistance mechanism. __________ Read here: https://ascopubs.org/doi/10.1200/PO.19.00141Advertisement
KRYSTAL-1: Adagrasib + Cetuximab Promise for KRASG12C Colorectal Cancer – Scott Kopetz, MD [AACR 2024] Colorectal 3 Mins Read
2024 Optimistic Advances in Colorectal Cancer: New Genetic Discoveries & Dancing Colorectal 5 Mins Read
Where do you see the greatest utility of ctDNA testing in patients with solid tumors? Colorectal 1 Min Read